Immunomodulatory and anti-inflammatory activities of statins

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 9, Issue 3, 2009, Pages 237-247

  Mira, Emilia ^a   Mañes, Santos ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ANTIINFLAMMATORY AGENT; CHEMOKINE; IMMUNOLOGIC FACTOR;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; ENDOTHELIUM CELL; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LIVER; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; REVIEW; STROKE; ANIMAL; ANTIGEN PRESENTATION; CAPILLARY PERMEABILITY; CELL DIFFERENTIATION; DRUG EFFECT; GENETICS; LEUKOCYTE; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGEN PRESENTATION; CAPILLARY PERMEABILITY; CELL DIFFERENTIATION; CHEMOKINES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; LEUKOCYTES; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, REGULATORY;

EID: 70350488075     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153009789044383     Document Type: Review

References (114)

1. Endo, A. (1992) The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res., 33(11), 1569-1582.
2. Zhou, Z.; Rahme, E. and Pilote, L. (2006) Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease progression. Am. Heart J., 151(2), 273-281.
3. Jain, M.K. and Ridker, P.M. (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug Discov., 4(12), 977-987.
4. Bronner, L.L.; Kanter, D.S. and Manson, J.E. (1995) Primary prevention of stroke. N. Engl. J. Med., 333(21), 1392-1400.
5. Libby, P. (2002) Inflammation in atherosclerosis. Nature, 420(6917), 868-874.
6. Albert, M.A.; Danielson, E.; Rifai, N. and Ridker, P.M. (2001) Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA, 286(1), 64-70.
7. Greenwood, J. and Mason, J.C. (2007) Statins and the vascular endothelial inflammatory response. Trends Immunol., 28(2), 88-98.
8. del Real, G.; Jiménez-Baranda, S.; Mira, E.; Lacalle, R.A.; Lucas, P.; Gómez-Moutón, C.; Alegret, M.; Peña, J.M.; Rodríguez-Zapata, M.; Alvarez-Mon, M.; Martínez-A., C. and Mañes, S. (2004) Statins inhibit HIV-1 infection by down-regulating Rho activity. J. Exp. Med., 200(4), 541-547.
9. Erkkila, L.; Jauhiainen, M.; Laitinen, K.; Haasio, K.; Tiirola, T.; Saikku, P. and Leinonen, M. (2005) Effect of simvastatin, an established lipid-lowering drug, on pulmonary Chlamydia pneumoniae infection in mice. Antimicrob. Agents Chemother., 49(9), 3959-3962.
10. Hackam, D.G.; Mamdani, M.; Li, P. and Redelmeier, D.A. (2006) Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet, 367(9508), 413-418.
11. Gupta, R.; Plantinga, L.C.; Fink, N.E.; Melamed, M.L.; Coresh, J.; Fox, C.S.; Levin, N.W. and Powe, N.R. (2007) Statin use and hospitalization for sepsis in patients with chronic kidney disease. JAMA, 297(13), 1455-1464.
12. Youssef, S.; Stuve, O.; Patarroyo, J.C.; Ruiz, P.J.; Radosevich, J.L.; Hur, E.M.; Bravo, M.; Mitchell, D.J.; Sobel, R.A.; Steinman, L. and Zamvil, S.S. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature, 420(6911), 78-84.
13. Aktas, O.; Waiczies, S.; Smorodchenko, A.; Dorr, J.; Seeger, B.; Prozorovski, T.; Sallach, S.; Endres, M.; Brocke, S.; Nitsch, R. and Zipp, F. (2003) Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med., 197(6), 725-733.
14. Lawman, S.; Mauri, C.; Jury, E.C.; Cook, H.T. and Ehrenstein, M.R. (2004) Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J. Immunol., 173(12), 7641-7646.
15. McCarey, D.W.; McInnes, I.B.; Madhok, R.; Hampson, R.; Scherbakov, O.; Ford, I.; Capell, H.A. and Sattar, N. (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet, 363(9426), 2015-2021.
16. Paraskevas, K.I. (2008) Statin treatment for rheumatoid arthritis: a promising novel indication. Clin. Rheumatol., 27(3), 281-287.
17. Kobashigawa, J.A.; Moriguchi, J.D.; Laks, H.; Wener, L.; Hage, A.; Hamilton, M.A.; Cogert, G.; Marquez, A.; Vassilakis, M.E.; Patel, J. and Yeatman, L. (2005) Ten-year follow-up of a randomized trial of pravastatin in heart transplant. patients. J. Heart Lung Transplant., 24(11), 1736-1740.
18. Masterson, R.; Hewitson, T.; Leikis, M.; Walker, R.; Cohney, S. and Becker, G. (2005) Impact of statin treatment on 1-year functional and histologic renal allograft outcome. Transplantation, 80(3), 332-338.
19. Broady, R. and Levings, M.K. (2008) Graft-versus-host disease: suppression by statins. Nat. Med., 14(11), 1155-1156.
20. Hamadani, M.; Awan, F.T. and Devine, S.M. (2008) The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Blood, 111(7), 3901-3902.
21. Varela, I.; Pereira, S.; Ugalde, A.P.; Navarro, C.L.; Suarez, M.F.; Cau, P.; Cadinanos, J.; Osorio, F.G.; Foray, N.; Cobo, J.; de Carlos, F.; Levy, N.; Freije, J.M. and Lopez-Otin, C. (2008) Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat. Med., 14(7), 767-772.
22. Demierre, M.F.; Higgins, P.D.; Gruber, S.B.; Hawk, E. and Lippman, S.M. (2005) Statins and cancer prevention. Nat. Rev. Cancer, 5(12), 930-942.
23. Cordle, A.; Koenigsknecht-Talboo, J.; Wilkinson, B.; Limpert, A. and Landreth, G. (2005) Mechanisms of statin-mediated inhibition of small G-protein function. J. Biol. Chem., 280(40), 34202-34209.
24. Greenwood, J.; Steinman, L. and Zamvil, S.S. (2006) Statin therapy and autoimmune disease: from protein prenylation to immuno-modulation. Nat. Rev. Immunol., 6(5), 358-370.
25. Weitz-Schmidt, G.; Welzenbach, K.; Brinkmann, V.; Kamata, T.; Kallen, J.; Bruns, C.; Cottens, S.; Takada, Y. and Hommel, U. (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med., 7(6), 687-692.
26. Monks, C.R.; Freiberg, B.A.; Kupfer, H.; Sciaky, N. and Kupfer, A. (1998) Three-dimensional segregation of supramolecular activation clusters in T cells. Nature, 395(6697), 82-86.
27. Dustin, M.L. and Shaw, A.S. (1999) Costimulation: building an immunological synapse. Science, 283(5402), 649-650.
28. Mañes, S.; del Real, G. and Martínez, A.C. (2003) Pathogens: raft hijackers. Nat. Rev. Immunol., 3(7), 557-568.
29. Mañes, S. and Viola, A. (2006) Lipid rafts in lymphocyte activation and migration. Mol. Membr. Biol., 23(1), 59-69.
30. Kwak, B.; Mulhaupt, F.; Myit, S. and Mach, F. (2000) Statins as a newly recognized type of immunomodulator. Nat. Med., 6(12), 1399-1402.
31. Lee, S.; Qin, H. and Benveniste, E. (2008) The IFN-gamma-induced transcriptional program of the CIITA gene is inhibited by statins. Eur. J. Immunol., 38(8), 2325-2336.
32. Kuipers, H.F. and van den Elsen, P.J. (2005) Statins and control of MHC2TA gene transcription. Nat. Med., 11(4), 365-366.
33. Muldoon, M.F.; Flory, J.D.; Marsland, A.; Manuck, S.B.; Whiteside, T.L. and Rabin, B. (1997) Effects of lovastatin on the immune system. Am. J. Cardiol., 80(10), 1391-1394.
34. Mira, E.; Leon, B.; Barber, D.F.; Jimenez-Baranda, S.; Goya, I.; Almonacid, L.; Marquez, G.; Zaballos, A.; Martinez, A.C.; Stein, J.V.; Ardavin, C. and Mañes, S. (2008) Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. J. Immunol., 181(5), 3524-3534.
35. Yilmaz, A.; Reiss, C.; Tantawi, O.; Weng, A.; Stumpf, C.; Raaz, D.; Ludwig, J.; Berger, T.; Steinkasserer, A.; Daniel, W.G. and Garlichs, C.D. (2004) HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis, 172(1), 85-93.
36. Schonbeck, U.; Gerdes, N.; Varo, N.; Reynolds, R.S.; Horton, D.B.; Bavendiek, U.; Robbie, L.; Ganz, P.; Kinlay, S. and Libby, P. (2002) Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation, 106(23), 2888-2893.
37. Wagner, A.H.; Gebauer, M.; Guldenzoph, B. and Hecker, M. (2002) 3-hydroxy-3-methylglutaryl coenzyme A reductase independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler. Thromb. Vasc. Biol., 22(11), 1784-1789.
38. Jury, E.C.; Isenberg, D.A.; Mauri, C. and Ehrenstein, M.R. (2006) Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J. Immunol., 177(10), 7416-7422.
39. Dunn, S.E.; Youssef, S.; Goldstein, M.J.; Prod'homme, T.; Weber, M.S.; Zamvil, S.S. and Steinman, L. (2006) Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J. Exp. Med., 203(2), 401-412.
40. + T cells. Annu. Rev. Immunol., 12, 635-673.
41. Abbas, A.K.; Murphy, K.M. and Sher, A. (1996) Functional diversity of helper T lymphocytes. Nature, 383(6603), 787-793.
42. Dong, C. (2008) Th17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol., 8(5), 337-348.
43. Chen, Z.; Laurence, A. and O'Shea, J.J. (2007) Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin. Immunol., 19(6), 400-408.
44. Stanislaus, R.; Gilg, A.G.; Singh, A.K. and Singh, I. (2002) Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin. Neurosci. Lett., 333(3), 167-170.
45. Leung, B.P.; Sattar, N.; Crilly, A.; Prach, M.; McCarey, D.W.; Payne, H.; Madhok, R.; Campbell, C.; Gracie, J.A.; Liew, F.Y. and McInnes, I.B. (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol., 170(3), 1524-1530.
46. Azuma, R.W.; Suzuki, J.; Ogawa, M.; Futamatsu, H.; Koga, N.; Onai, Y.; Kosuge, H. and Isobe, M. (2004) HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovasc. Res., 64(3), 412-420.
47. Paintlia, A.S.; Paintlia, M.K.; Singh, A.K.; Stanislaus, R.; Gilg, A.G.; Barbosa, E. and Singh, I. (2004) Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin. J. Neurosci. Res., 77(1), 63-81.
48. Liu, W.; Li, W.M.; Gao, C. and Sun, N.L. (2005) Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. J. Autoimmun., 25(4), 258-263.
49. Thomas, P.B.; Albini, T.; Giri, R.K.; See, R.F.; Evans, M. and Rao, N.A. (2005) The effects of atorvastatin in experimental autoimmune uveitis. Br. J. Ophthalmol., 89(3), 275-279.
50. Aprahamian, T.; Bonegio, R.; Rizzo, J.; Perlman, H.; Lefer, D.J.; Rifkin, I.R. and Walsh, K. (2006) Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J. Immunol., 177(5), 3028-3034.
51. Li, W.M.; Liu, W.; Gao, C. and Zhou, B.G. (2006) Immunoregulatory effects of atorvastatin on experimental autoimmune myocarditis in Lewis rats. Immunol. Cell Biol., 84(3), 274-280.
52. Kanda, H.; Yokota, K.; Kohno, C.; Sawada, T.; Sato, K.; Yamaguchi, M.; Komagata, Y.; Shimada, K.; Yamamoto, K. and Mimura, T. (2007) Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Mod. Rheumatol., 17(5), 364-368.
53. Zeiser, R.; Youssef, S.; Baker, J.; Kambham, N.; Steinman, L. and Negrin, R.S. (2007) Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood, 110(13), 4588-4598.
54. Palmer, G.; Chobaz, V.; Talabot-Ayer, D.; Taylor, S.; So, A.; Gabay, C. and Busso, N. (2004) Assessment of the efficacy of different statins in murine collagen-induced arthritis. Arthritis Rheum., 50(12), 4051-4059.
55. Menzies, D.; Nair, A.; Meldrum, K.T.; Fleming, D.; Barnes, M. and Lipworth, B.J. (2007) Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J. Allergy Clin. Immunol., 119(2), 328-335.
56. Nath, N.; Giri, S.; Prasad, R.; Singh, A.K. and Singh, I. (2004) Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J. Immunol., 172(2), 1273-1286.
57. Jorritsma, P.J.; Brogdon, J.L. and Bottomly, K. (2003) Role of TCR-induced extracellular signal-regulated kinase activation in the regulation of early IL-4 expression in naive CD4+ T cells. J. Immunol., 170(5), 2427-2434.
58. + lymphocytes. J. Immunol., 180(10), 6988-6996.
59. Iwakura, Y. and Ishigame, H. (2006) The IL-23/IL-17 axis in inflammation. J. Clin. Invest., 116(5), 1218-1222.
60. Aggarwal, S.; Ghilardi, N.; Xie, M.H.; de Sauvage, F.J. and Gurney, A.L. (2003) Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem., 278(3), 1910-1914.
61. Ivanov, I.I.; McKenzie, B.S.; Zhou, L.; Tadokoro, C.E.; Lepelley, A.; Lafaille, J.J.; Cua, D.J. and Littman, D.R. (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell, 126(6), 1121-1133.
62. Elliott, J. and Johnston, J.A. (2004) SOCS: role in inflammation, allergy and homeostasis. Trends Immunol., 25(8), 434-440.
63. + regulatory T cells. Nat. Immunol., 4(4), 330-336.
64. Hori, S.; Nomura, T. and Sakaguchi, S. (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science, 299(5609), 1057-1061.
65. Belkaid, Y. and Oldenhove, G. (2008) Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity, 29(3), 362-371.
66. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med., 198(12), 1875-1886.
67. Faria, A.M. and Weiner, H.L. (2005) Oral tolerance. Immunol. Rev., 206, 232-259.
68. Roncarolo, M.G.; Gregori, S.; Battaglia, M.; Bacchetta, R.; Fleischhauer, K. and Levings, M.K. (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev., 212, 28-50.
69. + Treg-mediated suppression. Trends Immunol., 29(7), 337-342.
70. Vignali, D.A.; Collison, L.W. and Workman, C.J. (2008) How regulatory T cells work. Nat. Rev. Immunol., 8(7), 523-532.
71. Huang, C.T.; Workman, C.J.; Flies, D.; Pan, X.; Marson, A.L.; Zhou, G.; Hipkiss, E.L.; Ravi, S.; Kowalski, J.; Levitsky, H.I.; Powell, J.D.; Pardoll, D.M.; Drake, C.G. and Vignali, D.A. (2004) Role of LAG-3 in regulatory T cells. Immunity, 21(4), 503-513.
72. Fallarino, F.; Grohmann, U.; Hwang, K.W.; Orabona, C.; Vacca, C.; Bianchi, R.; Belladonna, M.L.; Fioretti, M.C.; Alegre, M.L. and Puccetti, P. (2003) Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol., 4(12), 1206-1212.
73. Asseman, C.; Mauze, S.; Leach, M.W.; Coffman, R.L. and Powrie, F. (1999) An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med., 190(7), 995-1004.
74. + regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med., 194(5), 629-644.
75. + T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J. Immunol., 178(6), 3447-3456.
76. Sakaguchi, S.; Sakaguchi, N.; Asano, M.; Itoh, M. and Toda, M. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol., 155(3), 1151-1164.
77. Tang, Q.; Henriksen, K.J.; Bi, M.; Finger, E.B.; Szot, G.; Ye, J.; Masteller, E.L.; McDevitt, H.; Bonyhadi, M. and Bluestone, J.A. (2004) In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med., 199(11), 1455-1465.
78. Bennett, C.L.; Christie, J.; Ramsdell, F.; Brunkow, M.E.; Ferguson, P.J.; Whitesell, L.; Kelly, T.E.; Saulsbury, F.T.; Chance, P.F. and Ochs, H.D. (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet., 27(1), 20-21.
79. Brunkow, M.E.; Jeffery, E.W.; Hjerrild, K.A.; Paeper, B.; Clark, L.B.; Yasayko, S.A.; Wilkinson, J.E.; Galas, D.; Ziegler, S.F. and Ramsdell, F. (2001) Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet., 27(1), 68-73.
80. Wildin, R.S.; Ramsdell, F.; Peake, J.; Faravelli, F.; Casanova, J.L.; Buist, N.; Levy-Lahad, E.; Mazzella, M.; Goulet, O.; Perroni, L.; Bricarelli, F.D.; Byrne, G.; McEuen, M.; Proll, S.; Appleby, M. and Brunkow, M.E. (2001) X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet., 27(1), 18-20.
81. Prod'homme, T.; Weber, M.S. and Zamvil, S.S. (2007) T effectors outfox T regulators in autoimmunity. Nat. Med., 13(4), 411-413.
82. + T cells. Atherosclerosis, 197(2), 829-839.
83. Springer, T.A. (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell, 76(2), 301-314.
84. Mañes, S.; Gómez-Moutón, C.; Lacalle, R.A.; Jiménez-Baranda, S.; Mira, E. and Martínez-A., C. (2005) Mastering time and space: immune cell polarization and chemotaxis. Semin. Immunol., 17(1), 77-86.
85. Stalker, T.J.; Lefer, A.M. and Scalia, R. (2001) A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br. J. Pharmacol., 133(3), 406-412.
86. Li, D.; Chen, H.; Romeo, F.; Sawamura, T.; Saldeen, T. and Mehta, J.L. (2002) Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J. Pharmacol. Exp. Ther., 302(2), 601-605.
87. Prasad, R.; Giri, S.; Nath, N.; Singh, I. and Singh, A.K. (2005) Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction. J. Neurochem., 94(1), 204-214.
88. Weber, C.; Erl, W.; Weber, K.S. and Weber, P.C. (1997) HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J. Am. Coll. Cardiol., 30(5), 1212-1217.
89. Takeuchi, S.; Kawashima, S.; Rikitake, Y.; Ueyama, T.; Inoue, N.; Hirata, K. and Yokoyama, M. (2000) Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. Biochem. Biophys. Res. Commun., 269(1), 97-102.
90. Yoshida, M.; Sawada, T.; Ishii, H.; Gerszten, R.E.; Rosenzweig, A.; Gimbrone, M.A., Jr.; Yasukochi, Y. and Numano, F. (2001) HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler. Thromb. Vasc. Biol., 21(7), 1165-1171.
91. Rezaie-Majd, A.; Prager, G.W.; Bucek, R.A.; Schernthaner, G.H.; Maca, T.; Kress, H.G.; Valent, P.; Binder, B.R.; Minar, E. and Baghestanian, M. (2003) Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol., 23(3), 397-403.
92. Li, W.; Asagami, T.; Matsushita, H.; Lee, K.H. and Tsao, P.S. (2005) Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice. J. Pharmacol. Exp. Ther., 313(2), 557-562.
93. Xenos, E.S.; Stevens, S.L.; Freeman, M.B.; Cassada, D.C. and Goldman, M.H. (2005) Nitric oxide mediates the effect of fluvastatin on intercellular adhesion molecule-1 and platelet endothelial cell adhesion molecule-1 expression on human endothelial cells. Ann. Vasc. Surg., 19(3), 386-392.
94. Liu, L.; Moesner, P.; Kovach, N.L.; Bailey, R.; Hamilton, A.D.; Sebti, S.M. and Harlan, J.M. (1999) Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). J. Biol. Chem., 274(47), 33334-33340.
95. Mellado, M.; Rodriguez-Frade, J.M.; Mañes, S. and Martinez-A., C. (2001) Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu. Rev. Immunol., 19, 397-421.
96. Luster, A. (1998) Chemokines: chemotactic cytokines that mediate inflammation. N. Engl. J. Med., 338(7), 436-445.
97. Romano, M.; Diomede, L.; Sironi, M.; Massimiliano, L.; Sottocorno, M.; Polentarutti, N.; Guglielmotti, A.; Albani, D.; Bruno, A.; Fruscella, P.; Salmona, M.; Vecchi, A.; Pinza, M. and Mantovani, A. (2000) Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest., 80(7), 1095-1100.
98. Ifergan, I.; Wosik, K.; Cayrol, R.; Kebir, H.; Auger, C.; Bernard, M.; Bouthillier, A.; Moumdjian, R.; Duquette, P. and Prat, A. (2006) Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann. Neurol., 60(1), 45-55.
99. Veillard, N.R.; Braunersreuther, V.; Arnaud, C.; Burger, F.; Pelli, G.; Steffens, S. and Mach, F. (2006) Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis, 188(1), 51-58.
100. Zineh, I.; Luo, X.; Welder, G.J.; Debella, A.E.; Wessel, T.R.; Arant, C.B.; Schofield, R.S. and Chegini, N. (2006) Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors. Pharmacotherapy, 26(3), 333-340.
101. Breland, U.M.; Halvorsen, B.; Hol, J.; Oie, E.; Paulsson-Berne, G.; Yndestad, A.; Smith, C.; Otterdal, K.; Hedin, U.; Waehre, T.; Sandberg, W.J.; Froland, S.S.; Haraldsen, G.; Gullestad, L.; Damas, J.K.; Hansson, G.K. and Aukrust, P. (2008) A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque destabilization: downregulatory effects of statins. Arterioscler. Thromb Vasc. Biol., 28(5), 1005-1011.
102. Smith, C.; Halvorsen, B.; Otterdal, K.; Waehre, T.; Yndestad, A.; Fevang, B.; Sandberg, W.J.; Breland, U.M.; Froland, S.S.; Oie, E.; Gullestad, L.; Damas, J.K. and Aukrust, P. (2008) High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins. Cardiovasc. Res., 79(1), 195-203.
103. Kureishi, Y.; Luo, Z.; Shiojima, I.; Bialik, A.; Fulton, D.; Lefer, D.J.; Sessa, W.C. and Walsh, K. (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med., 6(9), 1004-1010.
104. Landsberger, M.; Jantzen, F.; Konemann, S. and Felix, S.B. (2005) Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells. Biochem. Biophys. Res. Commun., 336(4), 1005-1009.
105. Santizo, R.A.; Xu, H.L.; Galea, E.; Muyskens, S.; Baughman, V.L. and Pelligrino, D.A. (2002) Combined endothelial nitric oxide synthase upregulation and caveolin-1 downregulation decrease leukocyte adhesion in pial venules of ovariectomized female rats. Stroke, 33(2), 613-616.
106. Gelosa, P.; Cimino, M.; Pignieri, A.; Tremoli, E.; Guerrini, U. and Sironi, L. (2007) The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vasc. Health Risk Manag., 3(5), 567-577.
107. Cook-Mills, J.M.; Johnson, J.D.; Deem, T.L.; Ochi, A.; Wang, L. and Zheng, Y. (2004) Calcium mobilization and Rac1 activation are required for VCAM-1 (vascular cell adhesion molecule-1) stimulation of NADPH oxidase activity. Biochem. J., 378(Pt 2), 539-547.
108. Collins, T.; Read, M.A.; Neish, A.S.; Whitley, M.Z.; Thanos, D. and Maniatis, T. (1995) Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J., 9(10), 899-909.
109. Sun, J.; Steenbergen, C. and Murphy, E. (2006) S-nitrosylation: NO-related redox signaling to protect against oxidative stress. Antioxid. Redox Signal, 8(9-10), 1693-1705.
110. Hsu, M.; Muchova, L.; Morioka, I.; Wong, R.J.; Schroder, H. and Stevenson, D.K. (2006) Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo. Biochem. Biophys. Res. Commun., 343(3), 738-744.
111. Hopkins, P.N.; Wu, L.L.; Hunt, S.C.; James, B.C.; Vincent, G.M. and Williams, R.R. (1996) Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 16(2), 250-255.
112. Zeng, L.; Xu, H.; Chew, T.L.; Eng, E.; Sadeghi, M.M.; Adler, S.; Kanwar, Y.S. and Danesh, F.R. (2005) HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation. FASEB J., 19(13), 1845-1847.
113. van Wetering, S.; van den Berk, N.; van Buul, J.D.; Mul, F.P.; Lommerse, I.; Mous, R.; ten Klooster, J.P.; Zwaginga, J.J. and Hordijk, P.L. (2003) VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration. Am. J. Physiol. Cell Physiol., 285(2), C343-C352.
114. Chen, W.; Pendyala, S.; Natarajan, V.; Garcia, J.G. and Jacobson, J.R. (2008) Endothelial cell barrier protection by simvastatin: GTPase regulation and NADPH oxidase inhibition. Am. J. Physiol. Lung Cell Mol. Physiol., 295(4), L575-L583.